8-K: Aflac Reports Q2 Earnings Decline Amid Investment Losses

Aflac Incorporated reported a significant drop in second-quarter net earnings and total revenues, primarily driven by net investment losses, despite solid underlying operational performance in both its U.S. and Japan segments.

Summary

• Total revenues for the second quarter of 2025 were $4.2 billion, a 19.0% decrease from $5.1 billion in Q2 2024, mainly due to net investment losses.
• Net earnings were $599 million, or $1.11 per diluted share, down 65.9% from $1.8 billion, or $3.10 per diluted share, a year ago.
• Adjusted earnings for the quarter were $957 million, a 7.5% decrease from $1.0 billion in Q2 2024, with adjusted EPS at $1.78, down 2.7%.
• Net investment losses totaled $421 million in Q2 2025, compared to net investment gains of $696 million in Q2 2024.
• Aflac Japan's new annualized premium sales increased 23.2% to 20.7 billion yen ($143 million), driven by strong sales of the new Miraito cancer insurance product.
• Aflac U.S. net earned premiums increased 3.4% to $1.5 billion, and sales increased 2.7% to $340 million, benefiting from group life and disability products.
• The company repurchased $829 million of its common shares and paid $312 million in dividends during the quarter.
• Unencumbered holding company liquidity reached $5.1 billion, exceeding the minimum balance by $3.4 billion.
• The adjusted leverage ratio was 22.5%, remaining within the target range of 20% to 25%.

Sentiment

Score: 6

Explanation: While GAAP net earnings and total revenues saw a substantial decline due to market-driven investment losses, the underlying adjusted earnings showed a more modest decrease. Operational performance in both Japan and the U.S. remains strong with positive sales growth and persistency. The company's capital position is robust, and it continues to return capital to shareholders through buybacks and dividends. The overall sentiment is cautiously positive, acknowledging the market headwinds but highlighting the resilience of core operations.

Positives

• Aflac Japan achieved a significant 23.2% year-over-year increase in new annualized premium sales, primarily due to the new Miraito cancer insurance product.
• Aflac Japan maintained solid premium persistency at 93.7%, an increase of approximately 40 basis points year-over-year.
• Aflac U.S. reported a 3.4% increase in net earned premiums and a 2.7% increase in sales, with strong momentum in group life, disability, and network dental products.
• Aflac U.S. premium persistency improved by 50 basis points year-over-year to 79.2%.
• The company maintains strong capital ratios, with an estimated regulatory ESR above 240% for Japan and a Combined RBC ratio greater than 600% for the U.S.
• Aflac deployed $829 million in capital for share repurchases and paid $312 million in dividends in Q2 2025, demonstrating commitment to shareholder returns.
• Unencumbered holding company liquidity increased to $5.1 billion, which is $3.4 billion above the minimum balance, enhancing financial flexibility.
• The adjusted leverage ratio of 22.5% is within the company's target range of 20% to 25%.
• Favorable underwriting experience in Japan continues due to long-term trends in cancer treatment and hospitalization, leading to lower benefit ratios.
• The U.S. segment benefited from favorable underwriting on its growing long-term disability block.
• The U.S. expense ratio decreased by 60 basis points year-over-year, driven by improving scale and continuous focus on expense efficiency.
• The portfolio of first lien senior secured middle market loans performed well, with decreased CECL reserves of $23 million net of charge-offs.

Negatives

• Total revenues decreased by 19.0% to $4.2 billion in Q2 2025, primarily due to net investment losses.
• Net earnings plummeted by 65.9% to $599 million, or $1.11 per diluted share, compared to the prior year.
• The company recorded net investment losses of $421 million in Q2 2025, a significant reversal from net investment gains of $696 million in Q2 2024.
• Adjusted earnings decreased by 7.5% to $957 million, and adjusted EPS declined by 2.7% to $1.78.
• Aflac Japan's net earned premiums, adjusted net investment income, total adjusted revenues, and pretax adjusted earnings all declined in yen terms.
• Aflac Japan's expense ratio increased by 280 basis points year-over-year to 20.6%, primarily due to higher technology expenses.
• Aflac U.S. adjusted net investment income decreased by 5.0% for the quarter, mainly due to lower floating rate income.
• CECL reserves associated with the commercial real estate portfolio increased by $33 million net of charge-offs.
• Variable investment income ran $35 million below the company's long-term return expectations.
• Higher costs pertaining to business operations and increased interest expense contributed to higher total benefits and adjusted expenses in the Corporate segment.
• The company foreclosed on three loans, adding them to its real estate owned portfolio.

Risks

• Difficult conditions in global capital markets and the economy, including inflation.
• Defaults and credit downgrades of investments.
• Global fluctuations in interest rates and exposure to significant interest rate risk.
• Concentration of business in Japan.
• Limited availability of acceptable yen-denominated investments.
• Foreign currency fluctuations in the yen/dollar exchange rate.
• Differing interpretations applied to investment valuations.
• Significant valuation judgments in determination of expected credit losses recorded on investments.
• Decreases in financial strength or debt ratings.
• Decline in creditworthiness of other financial institutions.
• Ability to attract and retain qualified sales associates, brokers, employees, and distribution partners.
• Deviations in actual experience from pricing and reserving assumptions.
• Ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives.
• Interruption in telecommunication, information technology and other operational systems, or a failure to maintain security, confidentiality, integrity or privacy of sensitive data, including uncertainty regarding the impact of the incident involving unauthorized access to the Company's network in June 2025.
• Subsidiaries' ability to pay dividends to the Parent Company.
• Inherent limitations to risk management policies and procedures.
• Operational risks of third-party vendors.
• Tax rates applicable to the Company may change.
• Failure to comply with restrictions on policyholder privacy and information security.
• Extensive regulation and changes in law or regulation by governmental authorities.
• Competitive environment and ability to anticipate and respond to market trends.
• Catastrophic events, including those from climate change, epidemics, pandemics, natural disasters, war, terrorism, or other acts of violence.
• Ability to protect the Aflac brand and the Company's reputation.
• Ability to effectively manage key executive succession.
• Changes in accounting standards.
• Level and outcome of litigation or regulatory inquiries.
• Allegations or determinations of worker misclassification in the United States.

Future Outlook

The company is committed to generating profitable growth in the U.S. and Japan through distribution strategies and refreshed products, believing this will create long-term value for shareholders. The impact of growth initiatives on the expense ratio is expected to decrease as the company approaches scale. Management intends to continue a balanced approach of investing in growth and driving long-term operating efficiencies.

Management Comments

• "Aflac delivered solid earnings for the quarter and the first six months. We have continued to actively concentrate on generating profitable growth in the U.S. and Japan with distribution strategies and refreshed products. We believe our strategy will continue to create long-term value for shareholders." Daniel P. Amos, Chairman and CEO
• "Looking at our operations in Japan, I am pleased with Aflac Japan's 23.2% year-over-year sales increase and ongoing strong premium persistency. The strong sales were driven largely by sales of our newest cancer insurance product Miraito. We also continue to introduce the need for third sector protection to new and younger customers through our innovative first sector product Tsumitasu." Daniel P. Amos, Chairman and CEO
• "Overall, I believe we have the right strategy to meet our customers' financial protection needs throughout their different life stages." Daniel P. Amos, Chairman and CEO
• "In the U.S., I continue to be pleased with our premium persistency of 79.2%, in addition to our 3.4% increase in net earned premiums and 2.7% increase in sales. We are encouraged by the momentum we are seeing within all areas of our group business, especially our group life and disability as well as network dental." Daniel P. Amos, Chairman and CEO
• "We continue to focus on more profitable growth through our stronger underwriting discipline and improving the productivity of agents and brokers. We are seeing improvement in net earned premiums and continue our prudent approach to expense management and maintaining a strong pretax margin." Daniel P. Amos, Chairman and CEO
• "We continue to generate strong capital and cash flows while maintaining our commitment to prudent liquidity and capital management. We have been pleased with our investments, which have continued to produce strong net investment income. We treasure our 2024 milestone of 42 consecutive years of dividend increases and remain committed to extending this record, supported by our financial strength. We repurchased $829 million in shares for the quarter. We intend to continue our balanced approach of investing in growth and driving long-term operating efficiencies." Daniel P. Amos, Chairman and CEO
• "For the second quarter of 2025, adjusted earnings per diluted share decreased 2.7% year over year to $1.78, with a $0.04 positive impact from FX in the quarter." Max K. Brodn, Senior Executive Vice President CFO
• "Overall, we view these results in the quarter as solid." Max K. Brodn, Senior Executive Vice President CFO
• "Our portfolio of first lien senior secured middle market loans continued to perform well with decreased CECL reserves of $23 million in the quarter net of charge offs." Max K. Brodn, Senior Executive Vice President CFO
• "Our leverage was 22.5% for the quarter, which is within our target range of 20% to 25%." Max K. Brodn, Senior Executive Vice President CFO
• "This is intentional and part of our enterprise hedging program – protecting the economic value of Aflac Japan in U.S. dollar terms." Max K. Brodn, Senior Executive Vice President CFO
• "Adding this up, we feel that we are very well-positioned on an economic basis." Max K. Brodn, Senior Executive Vice President CFO

Industry Context

The filing highlights the significant impact of foreign currency fluctuations, particularly the yen/dollar exchange rate, on reported financial results for companies with substantial international operations like Aflac Japan. It also reflects the broader economic environment's influence on investment gains and losses, which heavily affected GAAP earnings. Aflac's focus on supplemental health insurance in the U.S. and specialized cancer and medical insurance in Japan positions it within specific, often less volatile, niches of the insurance industry, emphasizing product innovation (e.g., Miraito, Tsumitasu) to meet evolving customer needs and maintain market leadership.

Comparison to Industry Standards

• No specific comparable companies, projects, or global benchmarks were mentioned in the filing for direct comparison of results.

Stakeholder Impact

• Shareholders: Impacted by lower net earnings but benefit from continued share repurchases ($829 million in Q2) and consistent dividend payments ($0.58 per share declared), supported by strong capital and management's commitment to long-term value creation.
• Employees/Sales Associates/Brokers/Distribution Partners: The company's ability to attract and retain qualified personnel is a key risk, with ongoing efforts to improve agent and broker productivity.
• Customers: Benefit from new product offerings like Miraito and Tsumitasu, designed to meet evolving financial protection needs.
• Creditors: The company's debt raise to prefund maturities and strong capital ratios (ESR > 240%, RBC > 600%) indicate a stable financial position for debt obligations.
• Suppliers/Third-Party Vendors: Operational risks associated with third-party vendors are acknowledged as a potential challenge.

Next Steps

• Continue to actively concentrate on generating profitable growth in the U.S. and Japan with distribution strategies and refreshed products.
• Continue to introduce the need for third sector protection to new and younger customers through the innovative first sector product Tsumitasu in Japan.
• Focus on more profitable growth through stronger underwriting discipline and improving the productivity of agents and brokers in the U.S.
• Continue a prudent approach to expense management and maintaining a strong pretax margin.
• Continue a balanced approach of investing in growth and driving long-term operating efficiencies.
• Discuss results in further detail on the earnings call scheduled for August 6, 2025.

Key Dates

Recommendation

While GAAP net earnings and total revenues saw significant declines primarily due to net investment losses, the underlying adjusted earnings showed a more modest decrease. Operational performance in both Japan and the U.S. remains strong, with notable sales growth in Japan and improved persistency in both segments. The company maintains robust capital ratios, a healthy liquidity position, and continues its commitment to shareholder returns through dividends and share repurchases. The decline in GAAP earnings is largely attributable to market-driven investment fluctuations rather than core insurance operations. Investors should monitor the impact of foreign currency fluctuations and investment market conditions, but the core business fundamentals appear stable, warranting a hold position.

Keywords

Insurance, Supplemental Health Insurance, Cancer Insurance, Medical Insurance, Life Insurance, Disability Insurance, Financial Results, Earnings, Revenue, EPS, Adjusted Earnings, Share Repurchase, Dividends, Capital Management, Foreign Exchange, Japan Market, U.S. Market, Investment Losses, Risk Management, SEC Filing